ArticleThe Journal of international medical research2025
Diagnostic and therapeutic challenges in hyaline-vascular idiopathic multicentric Castleman disease: A case report.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of idiopathic multicentric Castleman disease typically requires serum interleukin-6 testing-often inaccessible in resource-limited settings. A female patient in her early 40s presented with 6-month progressive generalized pruritus, low-grade fever, fatigue, and painless multiregional lymphadenopathy. Laboratory studies showed systemic inflammation, computed tomography/ultrasound-confirmed bilateral axillary lymphadenopathy, splenomegaly, and serositis. Lymph node biopsy revealed hyaline-vascular features: atrophic germinal centers with a "lollipop-like" vasculature and "onion skin-like" lymphocyte proliferation. Interleukin-6 testing was unavailable. CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy (nine cycles) combined with thalidomide (100 mg/day, cycles 6-9) was administered. Significant lymph node regression normalized the levels of inflammatory markers, and partial remission was observed at the 1-year follow-up. Rigorous histopathology combined with dynamic inflammatory markers enables the diagnosis of idiopathic multicentric Castleman disease without interleukin-6 testing. CHOP-thalidomide is an effective alternative therapy in resource-constrained regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.